{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:31:38Z","timestamp":1792701098534,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clinthera.2026.03.023","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T21:48:50Z","timestamp":1777153730000},"page":"525-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing the Efficacy, Safety Profile, and Tolerability of Anti\u2013microRNA-328 Anti-sense (SHJ002) for Dry Eye Disease: A Randomized Phase 2 Trial"],"prefix":"10.1016","volume":"48","author":[{"given":"Ngamjit","family":"Kasetsuwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandor","family":"Jaross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usanee","family":"Reinprayoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeeshaan","family":"Daruwalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suh-Hang H.","family":"Juo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Ling","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.03.023_bib0001","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajo.2017.06.033","article-title":"Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older","volume":"182","author":"Farrand","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0002","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ceo.12183","article-title":"Prevalence of dry eye syndrome in an adult population","volume":"42","author":"Hashemi","year":"2014","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1542-0124(12)70082-4","article-title":"The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007)","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0004","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/jop.2021.0044","article-title":"MicroRNA therapy for dry eye disease","volume":"38","author":"Liao","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0006","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/biomedicines11020287","article-title":"Inhibition of microRNA-328 increases ocular mucin expression and conjunctival goblet cells","volume":"11","author":"Choo","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0007","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/1389557515666150324123208","article-title":"MicroRNA therapeutics: the next magic bullet?","volume":"15","author":"Simonson","year":"2015","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0008","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.preteyeres.2015.07.002","article-title":"Progress in corneal wound healing","volume":"49","author":"Ljubimov","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0009","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10557-023-07492-7","article-title":"Advances in microRNA therapy for heart failure: clinical trials, preclinical studies, and controversies","volume":"39","author":"Huang","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101634","article-title":"Current clinical trials with non-coding RNA-based therapeutics in malignant diseases: a systematic review","volume":"31","author":"Ito","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.clinthera.2026.03.023_bib0011","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.clinthera.2024.08.015","article-title":"Safety and tolerability of anti-microRNA-328 ophthalmic solution, SHJ002, in pediatric subjects: first-in-human clinical study","volume":"46","author":"Chen","year":"2024","journal-title":"Clin Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826000986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:35:39Z","timestamp":1779284139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826000986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0149291826000986"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the Efficacy, Safety Profile, and Tolerability of Anti\u2013microRNA-328 Anti-sense (SHJ002) for Dry Eye Disease: A Randomized Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}